William D. Baird, III net worth and biography

William Baird, III Biography and Net Worth

CFO of 2seventy bio

William “Chip” Baird has served as a member of our board of directors since June 2018. He joined bluebird bio, Inc. as Chief Financial Officer in February 2019 and previously served as Chief Financial Officer of Amicus Therapeutics, Inc., a pharmaceutical company, from April 2012 to December 2018. Mr. Baird holds an M.B.A. in finance from The Wharton School of the University of Pennsylvania and a B.S.F.S. in international affairs from the Edmund A. Walsh School of Foreign Service of Georgetown University.

What is William D. Baird, III's net worth?: The estimated net worth of William D. Baird, III is at least $632,433.20 as of January 5th, 2024. Mr. Baird, III owns 161,335 shares of 2seventy bio stock worth more than $632,433 as of November 14th. This net worth evaluation does not reflect any other assets that Mr. Baird, III may own. Learn More about William D. Baird, III's net worth.
How do I contact William D. Baird, III?: The corporate mailing address for Mr. Baird, III and other 2seventy bio executives is , , . 2seventy bio can also be reached via phone at 339-499-9300 and via email at [email protected]. Learn More on William D. Baird, III's contact information.
Has William D. Baird, III been buying or selling shares of 2seventy bio?: William D. Baird, III has not been actively trading shares of 2seventy bio over the course of the past ninety days. Most recently, William D. Baird III sold 1,380 shares of the business's stock in a transaction on Friday, January 5th. The shares were sold at an average price of $3.75, for a transaction totalling $5,175.00. Following the completion of the sale, the chief operating officer now directly owns 161,335 shares of the company's stock, valued at $605,006.25. Learn More on William D. Baird, III's trading history.
Who are 2seventy bio's active insiders?: 2seventy bio's insider roster includes William Baird, III (CFO), Philip Gregory (Insider), Nicola Heffron (COO), and Nick Leschly (CEO). Learn More on 2seventy bio's active insiders.
Are insiders buying or selling shares of 2seventy bio?: During the last twelve months, 2seventy bio insiders bought shares 2 times. They purchased a total of 630,000 shares worth more than $3,143,100.00. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 144,965 shares worth more than $564,664.26. The most recent insider tranaction occured on August, 14th when insider Jessica Snow sold 7,816 shares worth more than $33,765.12. Insiders at 2seventy bio own 7.2% of the company. Learn More about insider trades at 2seventy bio.
Information on this page was last updated on 8/14/2024.

William D. Baird, III Insider Trading History at 2seventy bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/5/2024	Sell	1,380	$3.75	$5,175.00	161,335
1/3/2024	Sell	33,651	$3.87	$130,229.37	162,715
8/22/2023	Sell	7,031	$5.49	$38,600.19	196,366
8/3/2023	Sell	6,906	$6.13	$42,333.78	203,397
2/13/2023	Sell	637	$12.86	$8,191.82	210,303
1/11/2023	Sell	1,077	$10.63	$11,448.51	78,797
1/9/2023	Sell	3,222	$10.33	$33,283.26	79,874
8/5/2022	Sell	4,152	$16.23	$67,386.96	83,096
7/15/2022	Sell	4,080	$13.81	$56,344.80	87,248
1/7/2022	Sell	896	$23.91	$21,423.36

William D. Baird, III Buying and Selling Activity at 2seventy bio

2seventy bio Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.92

$3.90

$4.32

50 Day Range

MA: $4.74

$4.13

$5.21

2 Week Range

Now: $3.92

$1.53

$6.40

Volume

283,585 shs

Average Volume

313,004 shs

Market Capitalization

$202.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late